BioMarin Pharmaceutical | BMRN - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Alnylam Pharmaceuticals USD 82.05M 12.76M 2026-06
Amgen USD 95.64B 94.98B 2026-06
Bayer EUR 675M 87M 2025-12
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 63.29M 48.34M 2026-06
Gilead Sciences USD 247M 7M 2026-06
Incyte USD 582K 13K 2026-06
Insmed USD 18.84M 1.24M 2026-06
Ionis Pharmaceuticals USD 18M 1000K 2026-06
Moderna USD 10.96B 527M 2026-06
Neurocrine Biosciences USD 1.1M 0 2024-03
PTC Therapeutics USD 3.25B 381.37M 2026-06
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR -25M 99.78M 2025-12
Sarepta Therapeutics USD 21.51M 205K 2026-06
Ultragenyx Pharmaceutical USD 22M 1000K 2026-06
United Therapeutics USD 2.9M 200K 2026-06
Vertex Pharmaceuticals USD 3.3M 0 2025-12